Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal sustained‑release implant for intravitreal injection use. It treats diabetic macular edema and chronic non‑infectious posterior uveitis in adult patients.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iluvien (fluocinolone acetonide) is used for ocular conditions that involve inflammation or fluid accumulation in the posterior segment of the eye.

Diabetic macular edema: reduces retinal swelling and improves visual acuity. Chronic non‑infectious posterior uveitis: controls intra‑ocular inflammation and helps preserve vision.

Iluvien may cause ocular adverse reactions that vary in frequency and severity.

Common Side Effects: - Increased intraocular pressure - Cataract formation - Ocular discomfort or irritation

Serious or Rare Side Effects: - Endophthalmitis (intraocular infection) - Retinal detachment - Persistent elevated intraocular pressure requiring surgical intervention

Prior to implantation, clinicians should assess ocular health and systemic risk factors. - Monitor intraocular pressure: schedule regular IOP checks after insertion. - Evaluate for cataract development: conduct periodic lens examinations. - Avoid in active ocular infection: postpone implantation until infection resolves. - Use caution in glaucoma patients: heightened risk of pressure spikes. - Assess systemic corticosteroid exposure: consider cumulative effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iluvien may interact with other therapies that influence ocular pressure or immune response.

Major Interactions (Avoid): - Concurrent intraocular corticosteroids: additive intraocular pressure elevation. - Systemic potent CYP3A4 inhibitors: may increase systemic exposure of fluocinolone acetonide.

Moderate Interactions (Monitor Closely): - Systemic immunosuppressants: heightened infection risk. - Anticoagulants or antiplatelet agents: increased bleeding risk during injection. - Topical non‑steroidal anti‑inflammatory drugs: may mask signs of inflammation. - Antiviral agents used for ocular infections: monitor for delayed healing.